Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Wenjie Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3182-8516; OpenAlex author ID A5059555627. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 11

  1. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Co-author DOI 10.1016/j.drup.2024.101079↗
  2. m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2021.739768↗
  3. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.omtn.2019.11.010↗
  4. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Co-author DOI 10.1158/0008-5472.can-19-1523↗
  5. Activating miRNA-mRNA network in gemcitabine-resistant pancreatic cancer cell associates with alteration of memory CD4+ T cells. Co-author DOI 10.21037/atm.2020.03.53↗
  6. Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. Co-author DOI 10.1002/path.5194↗
  7. MiR-24-3p Inhibits the Progression of Pancreatic Ductal Adenocarcinoma Through LAMB3 Downregulation. Co-author DOI 10.3389/fonc.2019.01499↗
  8. miR-23a-5p inhibits cell proliferation and invasion in pancreatic ductal adenocarcinoma by suppressing ECM1 expression. Co-author PMID 31217868↗
  9. Silencing circular RNA hsa_circ_0000977 suppresses pancreatic ductal adenocarcinoma progression by stimulating miR-874-3p and inhibiting PLK1 expression. Co-author DOI 10.1016/j.canlet.2018.02.014↗
  10. Retraction notice to "Silencing circular RNA hsa_circ_0000977 suppresses pancreatic ductal adenocarcinoma progression by stimulating miR-874-3p and inhibiting … Co-author DOI 10.1016/j.canlet.2018.09.027↗
  11. Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.19578↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaizhi Wang · 7 shared papers, 2017–2020 · strength 0.67
  2. Yingfang Fan · 4 shared papers, 2019–2024 · strength 0.53
  3. Shixiang Guo · 4 shared papers, 2017–2020 · strength 0.34
  4. Songsong Liu · 4 shared papers, 2017–2019 · strength 0.33
  5. Jianyou Gu · 3 shared papers, 2019–2020 · strength 0.32
  6. Yunchao Wang · 3 shared papers, 2017–2018 · strength 0.23
  7. Limin Xia · 2 shared papers, 2020–2021 · strength 0.23
  8. Tian Tao · 2 shared papers, 2019–2020 · strength 0.23
  9. Yingfang Fan · 2 shared papers, 2018 · strength 0.17
  10. Mengyu Sun · 1 shared paper, 2021 · strength 0.16
  11. Jin Peng He · 2 shared papers, 2019–2020 · strength 0.14
  12. Laura DeLong Wood · 2 shared papers, 2019–2020 · strength 0.14
  13. Christopher Lee Wolfgang · 2 shared papers, 2019–2020 · strength 0.14
  14. Michael Goggins · 2 shared papers, 2019–2020 · strength 0.14
  15. Nicholas Jason Roberts · 2 shared papers, 2019–2020 · strength 0.14
  16. Xianxing Wang · 1 shared paper, 2020 · strength 0.11
  17. Andrew T. Fesler · 1 shared paper, 2020 · strength 0.11
  18. Jingfang Ju · 1 shared paper, 2020 · strength 0.11
  19. Alina Hasanain · 1 shared paper, 2020 · strength 0.07
  20. Bo Huang · 1 shared paper, 2020 · strength 0.07
  21. Sandra Elisabeth Fischer · 1 shared paper, 2020 · strength 0.07
  22. Stefan Heinrich · 1 shared paper, 2020 · strength 0.07
  23. Kohei Fujikura · 1 shared paper, 2020 · strength 0.07
  24. Bernat Navarro-Serer · 1 shared paper, 2020 · strength 0.07
  25. Yea Ji Jeong · 1 shared paper, 2020 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.